Improved liquid chromatography-tandem mass spectrometry method for the analysis of eptifibatide in human plasma

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Aug 1;878(23):2094-100. doi: 10.1016/j.jchromb.2010.06.012. Epub 2010 Jun 18.

Abstract

A rapid, selective and highly sensitive high performance liquid chromatography-tandem mass spectrometry method (LC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of eptifibatide in human plasma. Eptifibatide and the internal standard (IS), EPM-05, were extracted from plasma samples using solid phase extraction. Chromatographic separation was performed on a C(18) column at a flow rate of 0.5 mL/min. Detection of eptifibatide and the IS was achieved by tandem mass spectrometry with an electrospray ionization (ESI) interface in positive ion mode. Traditional multiple reaction monitoring (MRM) using the transition of m/z 832.6-->m/z 646.4 and m/z 931.6-->m/z 159.4 was performed to quantify eptifibatide and the IS, respectively. The calibration curves were linear over the range of 1-1000 ng/mL with the lower limit of quantitation validated at 1 ng/mL. The intra- and inter-day precisions were within 13.3%, while the accuracy was within +/-7.6% of nominal values. The validated LC-MS/MS method was successfully applied for the evaluation of pharmacokinetic parameters of eptifibatide after intravenous (i.v.) administration of a 45 microg/kg bolus of eptifibatide to 8 healthy volunteers.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asian People
  • Chromatography, Liquid
  • Drug Stability
  • Eptifibatide
  • Female
  • Health
  • Humans
  • Male
  • Peptides / blood*
  • Peptides / chemistry
  • Peptides / pharmacokinetics
  • Platelet Aggregation Inhibitors / blood*
  • Platelet Aggregation Inhibitors / chemistry
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Reference Standards
  • Reproducibility of Results
  • Tandem Mass Spectrometry / methods*
  • Time Factors

Substances

  • Peptides
  • Platelet Aggregation Inhibitors
  • Eptifibatide